Pulmonary Arterial Hypertension Market Poised for Robust Growth Through 2034, Says DelveInsight
Key Players: Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed, Chugai Pharma, Keros Therapeutics, and Others
According to DelveInsight’s latest analysis, the Pulmonary Arterial Hypertension (PAH) market is projected to witness substantial growth through 2034, driven by rising disease prevalence, improved awareness, and continued innovation across therapeutic classes. Major companies shaping the competitive landscape include Aerovate Therapeutics, Novartis, Keros Therapeutics, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, United Therapeutics, Gilead Sciences, AstraZeneca, and others.
DelveInsight’s report, “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast 2034,” provides a comprehensive assessment of disease understanding, historical and forecasted epidemiology, and market trends across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Pulmonary Arterial Hypertension Market Outlook
The PAH market is expected to expand steadily during the forecast period, supported by higher diagnosis rates, advancements in disease management, and the anticipated launch of multiple late-stage pipeline therapies. These innovations are expected to redefine treatment paradigms and significantly influence competitive dynamics.
Understand how sotatercept is reshaping PAH treatment across the 7MM: https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=apac&utm_medium=pressrelease&utm_campaign=mpr
In 2022, the global PAH market was valued at approximately USD 4.9 billion, with the United States accounting for the largest share at nearly USD 3.9 billion. The EU4 and the UK together contributed around USD 816 million, representing close to 16% of total 7MM revenue.
Recent Developments Driving Market Evolution
January & March 2025: Merck reported positive Phase III ZENITH trial outcomes for WINREVAIR™ (sotatercept-csrk), demonstrating a 76% reduction in major morbidity and mortality events in high-risk PAH patients despite optimized background therapy.
October 2024: Inhibikase Therapeutics raised USD 110 million to support its Phase IIb ‘702’ trial in PAH.
July 2024: Aerovate Therapeutics announced a workforce reduction following the Phase IIb failure of AV-101, highlighting ongoing development risks in the PAH space.
Companies and Clinical Trial Activities in Pulmonary Arterial Hypertension
Japan represents a strategically important market within the 7MM, with localized clinical development efforts focused on generating population-specific safety and efficacy data to support regulatory approval.
Request a free sample to uncover epidemiology insights and regional growth opportunities in the Pulmonary Arterial Hypertension market.
MSD K.K. (Merck Sharp & Dohme, Japan)
Drug Candidate: Sotatercept (MK-7962 / WINREVAIR™)
Mechanism of Action: Sotatercept is a first-in-class activin signaling inhibitor, functioning as a recombinant fusion protein that traps activins and growth differentiation factors. By restoring balance in the BMP signaling pathway, it aims to reduce pulmonary vascular remodeling. The therapy is being evaluated as an add-on to standard PAH treatments.
Key Clinical Trials in Japan:
Phase III Local Study:
Identifiers: jRCT2031230046 / NCT05818137
Design: Randomized Phase III study assessing the efficacy and safety of sotatercept in Japanese patients with WHO Functional Class II/III PAH
Status: Active, not recruiting
Significance: Highlights Merck’s Japan-specific Phase III strategy to generate localized regulatory and safety data
Open-Label Extension Study:
Identifier: jRCT2061250021
Design: Open-label extension evaluating long-term safety and tolerability using weight-banded dosing
Status: Recruiting as of mid-2025
Latest Development: Sotatercept has received orphan drug designation in Japan, reinforcing its regulatory momentum. The ongoing Phase III and extension studies reflect MSD K.K.’s efforts to establish robust local evidence supporting future marketing authorization.
Explore Japan-specific PAH clinical development and global market trends download the full Pulmonary Arterial Hypertension Market Forecast Report.
Epidemiology Insights
In 2022, approximately 88,100 prevalent PAH cases were reported across the 7MM, with cases expected to increase modestly through 2032. Females were disproportionately affected compared to males. In Japan, PAH prevalence by WHO functional class showed a declining trend over the study period, despite continued clinical development activity.
Pipeline and Drug Uptake Trends
The PAH pipeline remains highly competitive, featuring innovative mechanisms such as activin signaling modulation, prostacyclin pathway enhancement, and inhaled formulations. Key pipeline candidates include sotatercept (Merck/Acceleron), ralinepag (United Therapeutics), seralutinib (Gossamer Bio), and treprostinil palmitil (Insmed), among others.
Table of Contents
1. Pulmonary Arterial Hypertension Market Report Introduction
2. Executive Summary for Pulmonary Arterial Hypertension
3. SWOT analysis of Pulmonary Arterial Hypertension
4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance
5. Pulmonary Arterial Hypertension Market Overview at a Glance
6. Pulmonary Arterial Hypertension Disease Background and Overview
7. Pulmonary Arterial Hypertension Epidemiology and Patient Population
8. Country-Specific Patient Population of Pulmonary Arterial Hypertension
9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices
10. Pulmonary Arterial Hypertension Unmet Needs
11. Pulmonary Arterial Hypertension Emerging Therapies
12. Pulmonary Arterial Hypertension Market Outlook
13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2020–2034)
14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies
15. Pulmonary Arterial Hypertension Market Drivers
16. Pulmonary Arterial Hypertension Market Barriers
17. Pulmonary Arterial Hypertension Appendix
18. Pulmonary Arterial Hypertension Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: [email protected]
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
